Moderna projected to have 10 products on market by 2027, revenue growth expected.

From Yahoo Finance: 2025-04-20 15:10:00

In the early days of the COVID-19 pandemic, Moderna was a top performer, with stock price increasing over 2,300%. However, recent years have seen disappointing stock performance and earnings due to declining demand for COVID vaccines and lower revenue from its RSV vaccine.

Moderna specializes in mRNA technology and successfully launched a COVID vaccine in record time in 2020, leading to high revenue. The company aims to have 10 products on the market by 2027, including vaccines for CMV, cancer, and norovirus. Despite setbacks, it has a higher clinical trial success rate than industry average.

By 2030, Moderna’s revenue could reach $6 billion with compound growth of 25% per year. The company is shifting its R&D focus to respiratory vaccines and oncology. With multiple products across various areas, Moderna is poised for success in the long term, making it an attractive investment opportunity.

Read more: Where Will Moderna Be in 5 Years?